{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:48:23Z","timestamp":1790635703473,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["H2020-668353"],"award-info":[{"award-number":["H2020-668353"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41397-021-00249-1","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T13:02:59Z","timestamp":1625230979000},"page":"533-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Economic evaluation in psychiatric pharmacogenomics: a systematic review"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3085-7799","authenticated-orcid":false,"given":"Kariofyllis","family":"Karamperis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8843-082X","authenticated-orcid":false,"given":"Maria","family":"Koromina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Papantoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8579-8933","authenticated-orcid":false,"given":"Maria","family":"Skokou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8959-0622","authenticated-orcid":false,"given":"Filippos","family":"Kanellakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mitropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanassios","family":"Vozikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-7776","authenticated-orcid":false,"given":"George P.","family":"Patrinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-4668","authenticated-orcid":false,"given":"Christina","family":"Mitropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"249_CR1","unstructured":"Hannah R, Max R. \u201cMental Health\u201d. 2018. https:\/\/ourworldindata.org\/mental-health. Accessed 10 Oct 2020."},{"key":"249_CR2","unstructured":"WHO. Mental disorders. 2019. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-disorders Accessed 10 Oct 2020."},{"key":"249_CR3","unstructured":"National Institute of Mental Health. 2019. https:\/\/www.nimh.nih.gov\/health\/statistics\/mental-illness.shtml. Accessed 10 Oct 2020."},{"key":"249_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.schres.2018.04.009","volume":"199","author":"A John","year":"2018","unstructured":"John A, McGregor J, Jones I, Lee SC, Walters JTR, Owen MJ, et al. Premature mortality among people with severe mental illness\u2014new evidence from linked primary care data. Schizophr Res. 2018;199:154\u201362.","journal-title":"Schizophr Res"},{"key":"249_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/wps.20384","volume":"16","author":"NH Liu","year":"2017","unstructured":"Liu NH, Daumit GL, Dua T, Aquila R, Charlson F, Cuijpers P, et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry. 2017;16:30\u201340.","journal-title":"World Psychiatry."},{"key":"249_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1099-176X(200003)3:1<3::AID-MHP68>3.0.CO;2-H","volume":"3","author":"P Berto","year":"2000","unstructured":"Berto P, D\u2019Ilario D, Ruffo P, Virgilio RDI, Rizzo F. Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ. 2000;3:3\u201310.","journal-title":"J Ment Health Policy Econ."},{"key":"249_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/mpr.139","volume":"12","author":"PS Wang","year":"2003","unstructured":"Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res. 2003;12:22\u201333.","journal-title":"Int J Methods Psychiatr Res."},{"key":"249_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.15252\/embr.201642951","volume":"17","author":"S Trautmann","year":"2016","unstructured":"Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep. 2016;17:1245\u20139.","journal-title":"EMBO Rep."},{"key":"249_CR9","unstructured":"OECD. OECD Health at a Glance 2019. In OECD iLibrary. 2019. https:\/\/www.oecd-ilibrary.org\/sites\/health_glance_eur-2018-4-en\/index.html?itemId=\/content\/component\/health_glance_eur-2018-4-en."},{"key":"249_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789\u2013858.","journal-title":"Lancet."},{"key":"249_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ijnp\/pyy024","volume":"22","author":"C Fabbri","year":"2019","unstructured":"Fabbri C, Corponi F, Souery D, Kasper S, Montgomery S, Zohar J, et al. The genetics of treatment-resistant depression: a critical review and future perspectives. Int J Neuropsychopharmacol. 2019;22:93\u2013104.","journal-title":"Int J Neuropsychopharmacol."},{"key":"249_CR12","doi-asserted-by":"publisher","first-page":"e8508","DOI":"10.1136\/bmj.e8508","volume":"345","author":"IM Anderson","year":"2012","unstructured":"Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ. 2012;345:e8508.","journal-title":"BMJ."},{"key":"249_CR13","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry."},{"key":"249_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/npp.2011.306","volume":"37","author":"J Undurraga","year":"2012","unstructured":"Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: Thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37:851\u201364.","journal-title":"Neuropsychopharmacology."},{"key":"249_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449\u201359.","journal-title":"Curr Psychiatry Rep."},{"key":"249_CR16","doi-asserted-by":"publisher","unstructured":"Mrazek MD, Mooneyham BW, Schooler JW. Insights from quiet minds: the converging fields of mindfulness and mind-wandering. 2014. https:\/\/doi.org\/10.1007\/978-3-319-01634-4_13.","DOI":"10.1007\/978-3-319-01634-4_13"},{"key":"249_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/mp.2008.116","volume":"15","author":"M Kato","year":"2010","unstructured":"Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15:473\u2013500.","journal-title":"Mol Psychiatry."},{"key":"249_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/FPC.0b013e32832e4bcd","volume":"19","author":"G Laje","year":"2009","unstructured":"Laje G, Allen AS, Akula N, Manji H, John Rush A, McMahon FJ. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics. 2009;19:666\u201374.","journal-title":"Pharmacogenet Genomics."},{"key":"249_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.mp.4001926","volume":"12","author":"A Serretti","year":"2007","unstructured":"Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247\u201357.","journal-title":"Mol Psychiatry."},{"key":"249_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/YPG.0b013e32832a506e","volume":"19","author":"SM Villafuerte","year":"2009","unstructured":"Villafuerte SM, Vallabhaneni K, \u015aliwerska E, McMahon FJ, Young EA, Burmeister M. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet. 2009;19:281\u201391.","journal-title":"Psychiatr Genet."},{"key":"249_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/tpj.2015.39","volume":"16","author":"O Alagoz","year":"2016","unstructured":"Alagoz O, Durham D, Kasirajan K. Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. Pharmacogenomics J. 2016;16:129\u201336. 2016","journal-title":"Pharmacogenomics J."},{"key":"249_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1200\/JCO.2013.49.5523","volume":"32","author":"JR Gardner","year":"2014","unstructured":"Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32:335\u201346.","journal-title":"J Clin Oncol."},{"key":"249_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ddr.20424","volume":"71","author":"S Vegter","year":"2010","unstructured":"Vegter S, Jansen E, Postma MJ, Boersma C. Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Dev Res. 2010;71:492\u2013501.","journal-title":"Drug Dev Res."},{"key":"249_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2165\/00019053-200826070-00005","volume":"26","author":"S Vegter","year":"2008","unstructured":"Vegter S, Boersma C, Rozenbaum M, Wilfert B, Navis G, Postma J. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics. 2008;26:569\u201387.","journal-title":"Pharmacoeconomics."},{"key":"249_CR25","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cpt.1007","volume":"103","author":"MP Goetz","year":"2018","unstructured":"Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and tamoxifen therapy. Clin Pharm Ther. 2018;103:770\u20137.","journal-title":"Clin Pharm Ther."},{"key":"249_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1124\/pr.112.007252","volume":"65","author":"JA Johnson","year":"2013","unstructured":"Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease-implications for personalized medicine\u2019. Pharm Rev. 2013;65:987\u20131009.","journal-title":"Pharm Rev."},{"key":"249_CR27","doi-asserted-by":"crossref","unstructured":"Mahungu T, Owen A. Current progress in the pharmacogenetics of infectious disease therapy. In: Tibayrenc M., editor. Genetics and Evolution of Infectious Disease. 2nd ed. Elsevier: Amsterdam; 2011.","DOI":"10.1016\/B978-0-12-384890-1.00020-0"},{"key":"249_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl J Med. 2008;358:568\u201379.","journal-title":"N. Engl J Med."},{"key":"249_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","volume":"102","author":"JK Hicks","year":"2017","unstructured":"Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, M\u00fcller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharm Ther. 2017;102:37\u201344.","journal-title":"Clin Pharm Ther."},{"key":"249_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/jpm10010003","volume":"10","author":"N Westergaard","year":"2020","unstructured":"Westergaard N, S\u00f8gaard Nielsen R, J\u00f8rgensen S, Vermehren C. Drug use in Denmark for drugs having pharmacogenomics (PGx) based dosing guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 drug\u2013gene pairs: Perspectives for introducing PGx test to polypharmacy patients. J Pers Med. 2020;10:3.","journal-title":"J Pers Med."},{"key":"249_CR31","doi-asserted-by":"publisher","first-page":"105538","DOI":"10.1016\/j.phrs.2021.105538","volume":"167","author":"Z Kordou","year":"2021","unstructured":"Kordou Z, Skokou M, Tsermpini EE, Chantratita W, Fukunaga K, Mushiroda T, et al. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data [published online ahead of print, 2021 Mar 9]. Pharm Res. 2021;167:105538.","journal-title":"Pharm Res."},{"key":"249_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9\u201362.","journal-title":"Pharmacopsychiatry."},{"key":"249_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-1288-1061","volume":"54","author":"CA Bousman","year":"2021","unstructured":"Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 2021;54:5\u201317.","journal-title":"Pharmacopsychiatry."},{"key":"249_CR34","doi-asserted-by":"publisher","first-page":"e0146262","DOI":"10.1371\/journal.pone.0146262","volume":"11","author":"EJJ Berm","year":"2016","unstructured":"Berm EJJ, De Looff M, Wilffert B, Boersma C, Annemans L, Vegter S, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS ONE 2016;11:e0146262.","journal-title":"PLoS ONE"},{"key":"249_CR35","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00213-017-4622-9","volume":"234","author":"K Peterson","year":"2017","unstructured":"Peterson K, Dieperink E, Anderson J, Boundy E, Ferguson L, Helfand M. Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology. 2017;234:1649\u201361.","journal-title":"Psychopharmacology."},{"key":"249_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","volume":"41","author":"CF Chiou","year":"2003","unstructured":"Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32\u201344.","journal-title":"Med Care"},{"key":"249_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/GIM.0b013e3182003294","volume":"13","author":"S Djalalov","year":"2011","unstructured":"Djalalov S, Musa Z, Mendelson M, Siminovitch K, Hoch J. A review of economic evaluations of genetic testing services and interventions (2004\u20132009). Genet Med. 2011;13:89\u201394.","journal-title":"Genet Med"},{"key":"249_CR38","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2165\/11537410-000000000-00000","volume":"28","author":"WB Wong","year":"2010","unstructured":"Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics. 2010;28:1001\u201313.","journal-title":"Pharmacoeconomics."},{"key":"249_CR39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41436-019-0667-y","volume":"22","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Swanson KM, Rojas RL, Wang Z, St. Sauver JL, Visscher SL, et al. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet Med. 2020;22:475\u201386.","journal-title":"Genet Med."},{"key":"249_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jacbts.2016.01.008","volume":"1","author":"KR King","year":"2016","unstructured":"King KR, Grazette LP, Paltoo DN, McDevitt JT, Sia SK, Barrett PM, et al. Point-of-care technologies for precision cardiovascular care and clinical research: National Heart, Lung, and Blood Institute Working Group. JACC Basic Transl Sci. 2016;1:73\u201386.","journal-title":"JACC Basic Transl Sci."},{"key":"249_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2217\/pme-2018-0074","volume":"15","author":"J Benitez","year":"2018","unstructured":"Benitez J, Cool CL, Scotti DJ. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Per Med. 2018;15:481\u201394.","journal-title":"Per Med."},{"key":"249_CR42","doi-asserted-by":"publisher","first-page":"e0169065","DOI":"10.1371\/journal.pone.0169065","volume":"11","author":"EJJ Berm","year":"2016","unstructured":"Berm EJJ, Gout-Zwart JJ, Luttjeboer J, Wilffert B, Postma MJ. A model based cost-effectiveness analysis of routine genotyping for CYP2D6 among older, depressed inpatients starting nortriptyline pharmacotherapy. PLoS ONE. 2016;11:e0169065.","journal-title":"PLoS ONE."},{"key":"249_CR43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.clinthera.2017.01.022","volume":"39","author":"LC Brown","year":"2017","unstructured":"Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clin Ther. 2017;39:592\u2013602.e1.","journal-title":"Clin Ther."},{"key":"249_CR44","first-page":"e146","volume":"20","author":"J Fagerness","year":"2014","unstructured":"Fagerness J, Fonseca E, Hess GP, Scott R, Gardner KR, Koffler M, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20:e146\u2013e156.","journal-title":"Am J Manag Care."},{"key":"249_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41397-017-0004-2","volume":"19","author":"FR Girardin","year":"2019","unstructured":"Girardin FR, Poncet A, Perrier A, Vernaz N, Pletscher M, F. Samer C, et al. Cost-effectiveness of HLA-DQB1\/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics J. 2019;19:211\u20138.","journal-title":"Pharmacogenomics J."},{"key":"249_CR46","first-page":"726","volume":"24","author":"EJ Groessl","year":"2018","unstructured":"Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm. 2018;24:726\u201334.","journal-title":"J Manag Care Spec Pharm."},{"key":"249_CR47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/bcpt.12093","volume":"113","author":"L Herbild","year":"2013","unstructured":"Herbild L, Andersen SE, Werge T, Rasmussen HB, J\u00fcrgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharm Toxicol. 2013;113:266\u201372.","journal-title":"Basic Clin Pharm Toxicol."},{"key":"249_CR48","first-page":"e357","volume":"21","author":"J Hornberger","year":"2015","unstructured":"Hornberger J, Li Q, Quinn B. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Am J Manag Care. 2015;21:e357\u2013e365.","journal-title":"Am J Manag Care."},{"key":"249_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/NDT.S145046","volume":"14","author":"A Maciel","year":"2018","unstructured":"Maciel A, Cullors A, Alukowiak A, Garces J. Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings. Neuropsychiatr Dis Treat. 2018;14:225\u201330.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"249_CR50","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40273-017-0587-0","volume":"35","author":"M Najafzadeh","year":"2017","unstructured":"Najafzadeh M, Garces JA, Maciel A. Economic evaluation of implementing a novel pharmacogenomic test (IDgenetix\u00ae) to guide treatment of patients with depression and\/or anxiety. Pharmacoeconomics. 2017;35:1297\u2013310.","journal-title":"Pharmacoeconomics."},{"key":"249_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.pnpbp.2011.08.013","volume":"36","author":"P Olgiati","year":"2012","unstructured":"Olgiati P, Bajo E, Bigelli M, De Ronchi D, Serretti A. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:147\u201354.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"249_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/01.jcp.0000177553.59455.24","volume":"25","author":"RH Perlis","year":"2005","unstructured":"Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, et al. Pharmacogenetic testing in the clinical management of schizophrenia: A decision-analytic model. J Clin Psychopharmacol. 2005;25:427\u201334.","journal-title":"J Clin Psychopharmacol."},{"key":"249_CR53","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/npp.2009.50","volume":"34","author":"RH Perlis","year":"2009","unstructured":"Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34:2227\u201336.","journal-title":"Neuropsychopharmacology."},{"key":"249_CR54","doi-asserted-by":"publisher","unstructured":"Rejon-Parrilla JC, Nuijten M, Redekop WK, Gaultney JG (2014). Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia. Health Policy Technol. 2014. https:\/\/doi.org\/10.1016\/j.hlpt.2014.08.004.","DOI":"10.1016\/j.hlpt.2014.08.004"},{"key":"249_CR55","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/15622975.2011.572998","volume":"12","author":"A Serretti","year":"2011","unstructured":"Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry. 2011;12:501\u201315.","journal-title":"World J Biol Psychiatry."},{"key":"249_CR56","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41397-019-0070-8","volume":"19","author":"RL Sluiter","year":"2019","unstructured":"Sluiter RL, Janzing JGE, van der Wilt GJ, Kievit W, Teichert M. An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care. Pharmacogenomics J. 2019;19:480\u20139.","journal-title":"Pharmacogenomics J."},{"key":"249_CR57","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1185\/03007995.2015.1063483","volume":"31","author":"JG Winner","year":"2015","unstructured":"Winner JG, Carhart JM, Altar CA, Goldfarb S, Allen JD, Lavezzari G, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;31:1633\u201343.","journal-title":"Curr Med Res Opin."},{"key":"249_CR58","first-page":"219","volume":"16","author":"JG Winner","year":"2013","unstructured":"Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Disco Med. 2013;16:219\u201327.","journal-title":"Disco Med."},{"key":"249_CR59","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2217\/pgs-2016-0052","volume":"17","author":"C Mitropoulou","year":"2016","unstructured":"Mitropoulou C, Fragoulakis V, Rakicevic LB, Novkovic MM, Vozikis A, Matic DM, et al. Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Pharmacogenomics. 2016;17:1775\u201384.","journal-title":"Pharmacogenomics."},{"key":"249_CR60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2217\/pgs.14.167","volume":"16","author":"C Mitropoulou","year":"2015","unstructured":"Mitropoulou C, Fragoulakis V, Bozina N, Vozikis A, Supe S, Bozina T, et al. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics. 2015;16:137\u201348.","journal-title":"Pharmacogenomics."},{"key":"249_CR61","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/occmed\/kqn124","volume":"58","author":"C Cooper","year":"2008","unstructured":"Cooper C, Dewe P. Well-being\u2014Absenteeism, presenteeism, costs and challenges. Occup Med. 2008;58:522\u20134.","journal-title":"Occup Med."},{"key":"249_CR62","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jval.2016.12.006","volume":"20","author":"J Kigozi","year":"2017","unstructured":"Kigozi J, Jowett S, Lewis M, Barton P, Coast J. The estimation and inclusion of presenteeism costs in applied economic evaluation: a systematic review. Value Health. 2017;20:496\u2013506.","journal-title":"Value Health."},{"key":"249_CR63","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/cpt.1432","volume":"106","author":"CA Bousman","year":"2019","unstructured":"Bousman CA, Zierhut H, M\u00fcller DJ. Navigating the labyrinth of pharmacogenetic testing: a guide to test selection. Clin Pharm Ther. 2019;106:309\u201312.","journal-title":"Clin Pharm Ther."},{"key":"249_CR64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrg.2017.108","volume":"19","author":"K Payne","year":"2018","unstructured":"Payne K, Gavan SP, Wright SJ, Thompson AJ. Cost-effectiveness analyses of genetic and genomic diagnostic tests. Nat Rev Genet. 2018;19:235\u201346.","journal-title":"Nat Rev Genet."},{"key":"249_CR65","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, Mavros P, J\u00f6nsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518\u201328.","journal-title":"Value Health."},{"key":"249_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","volume":"19","author":"K Claxton","year":"2015","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and care excellence cost-effectiveness threshold. Health Technol Assess. 2015;19:1\u2013vi.","journal-title":"Health Technol Assess."},{"key":"249_CR67","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19:929\u201335.","journal-title":"Value Health."},{"key":"249_CR68","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/hec.864","volume":"13","author":"N Devlin","year":"2004","unstructured":"Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437\u201352.","journal-title":"Health Econ."},{"key":"249_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S. \u2018Pricing and reimbursement of orphan drugs: The need for more transparency\u2019. Orphanet J Rare Dis. 2011;6:42.","journal-title":"Orphanet J Rare Dis."},{"key":"249_CR70","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1258\/135581906775094235","volume":"11","author":"S Birch","year":"2006","unstructured":"Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy. 2006;11:46\u201351.","journal-title":"J Health Serv Res Policy."},{"key":"249_CR71","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharm Ther. 2013;138:103\u201341.","journal-title":"Pharm Ther."},{"key":"249_CR72","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","volume":"28","author":"J Petrovi\u0107","year":"2020","unstructured":"Petrovi\u0107 J, Pe\u0161i\u0107 V, Lauschke VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2020;28:88\u201394.","journal-title":"Eur J Hum Genet."},{"key":"249_CR73","first-page":"1","volume":"11","author":"MS Zastrozhin","year":"2017","unstructured":"Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmgenomics Pers Med. 2017;11:1\u20135.","journal-title":"Pharmgenomics Pers Med."},{"key":"249_CR74","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/1389200217666151210125831","volume":"17","author":"G Ragia","year":"2016","unstructured":"Ragia G, Dahl ML, Manolopoulos VG. Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs. Curr Drug Metab. 2016;17:227\u201336.","journal-title":"Curr Drug Metab."},{"key":"249_CR75","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/cpt.743","volume":"102","author":"GP Patrinos","year":"2017","unstructured":"Patrinos GP, Mitropoulou C. Measuring the value of pharmacogenomics evidence. Clin Pharm Ther. 2017;102:739\u201341.","journal-title":"Clin Pharm Ther"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-021-00249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-021-00249-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-021-00249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:45Z","timestamp":1684616445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00249-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1038\/s41397-021-00249-1","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"5 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. GPP is Full Member and national Representative of the European Medicines Agency, Committee for Human medicinal Product (CHMP) \u2013 Pharmacogenomics Working Party (Amsterdam, the Netherlands) and member of the Clinical Pharmacogenetics Implementation Consortium (CPIC). DJM is a member of CPIC and co-investigator in two pharmacogenetic studies where genetic test kits were provided as in-kind contribution by Myriad Neuroscience. No payment or any equity, stocks, or options from any pharmacogenetic testing company was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}